EE215 Pharmacoeconomic Analysis of Adjuvant Nivolumab for Patients With Resected Esophageal or Gastroesophageal Junction Cancer in Switzerland
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.464
https://www.valueinhealthjournal.com/article/S1098-3015(22)02668-7/fulltext
Section Title :
Section Order :
12273
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02668-7&doi=10.1016/j.jval.2022.09.464